Search | OpenScholar

Search results

374 results found

Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol 2013;20:180-7.

Publication: Journal Article

AH, Schapira, P Barone, RA Hauser, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, and W Poewe. 2013. “Success Rate, Efficacy, and Safety/Tolerability of Overnight Switching from Immediate- to Extended-Release Pramipexole in Advanced Parkinson’s Disease. Eur J Neurol 2013;20:180-7.”. Eur J Neurol.

Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.

Publication: Journal Article

Chen, JJ, Y Han, J Tang, L Portillo, RA Hauser, and K Dashtipour. 2018. “Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-Analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.”. Ann Pharmacother.

A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol 2016;263:772-780.

Publication: Journal Article

Han, Y, AL Stevens, K Dashtipour, RA Hauser, and Z Mari. 2016. “A Mixed Treatment Comparison to Compare the Efficacy and Safety of Botulinum Toxin Treatments for Cervical Dystonia. J Neurol 2016;263:772-780.”. J Neurol .

Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord 2020;77:141-145.

Publication: Journal Article

Bhidayasiri, R, JM Kane, KP Frei, SN Caroff, CU Correll, S Fahn, J Jankovic, RA Hauser, and DD Truong. 2020. “Expanding Phenomenologic Heterogeneity of Tardive Syndromes: Time for an Updated Assessment Tool. Parkinsonism Relat Disord 2020;77:141-145.”. Parkonsonism Relat Disord.

Communicating with participants during the conduct of multi-center clinical trials. Clin Trials 2016;13:592-596.

Publication: Journal Article

Augustine, EF, ER Dorsey, RA Hauser, JJ Elm, BC Tilley, and KK Kieburtz. 2016. “Communicating With Participants During the Conduct of Multi-Center Clinical Trials. Clin Trials 2016;13:592-596.”. Clin Trials.

Levodopa-carbidopa intestinal gelin advanced Parkinson's disease: Final 12-month, open-label results. Mov Disord 2015;30:500-9.

Publication: Journal Article

Fernandez, HH, DG Standaert, RA Hauser, AE Lang, VS Fung, F Klostermann, MF Lew, et al. 2015. “Levodopa-Carbidopa Intestinal Gelin Advanced Parkinson’s Disease: Final 12-Month, Open-Label Results. Mov Disord 2015;30:500-9.”. Mov Disord.

α-Synuclein in Parkinson's disease: getting to the core of the matter. Lancet Neurol 2015;14:785-6.

Publication: Journal Article

Hauser, RA. 2015. “α-Synuclein in Parkinson’s Disease: Getting to the Core of the Matter. Lancet Neurol 2015;14:785-6.”. Lancet Neurol.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013;28:1823-31.

Publication: Journal Article

Group, Parkinson Study. 2013. “Phase II Safety, Tolerability, and Dose Selection Study of Isradipine As a Potential Disease-Modifying Intervention in Early Parkinson’s Disease (STEADY-PD). Mov Disord 2013;28:1823-31.”. Mov Disord.

IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother. 2012;12:133-40.

Publication: Journal Article

Hauser, RA. 2012. “IPX066: a Novel Carbidopa-Levodopa Extended-Release Formulation. Expert Rev Neurother. 2012;12:133-40.”. Expert Rev Neurother.

Design innovations and baseline findings in a long-term Parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson’s Disease Long-Term Study-1. Mov Disord 2012; 27:1513-1521.

Publication: Journal Article

Elm, JJ, and The NINDS NET-PD Investigators. 2012. “Design Innovations and Baseline Findings in a Long-Term Parkinson’s Trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson’s Disease Long-Term Study-1. Mov Disord 2012; 27:1513-1521.”. Mov Disord.